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Abstract
Background: This study evaluates the epidemiological impact of RVGE hospitalisation in the Veneto Region during
the period spanning from 2000-2007 along with the associated costs. The analysis was conducted in an area where
rotavirus vaccination is not included into immunization programmes and is an attempt to assess the potential
benefits of such introduction.
Methods: To update the estimates of acute RVGE hospitalisation rates in children ≤5 years in the Veneto Region,
we conducted an 8 year retrospective observational population-based analysis (2000-2007).
Results: Over the study period, a total of 4,119 admissions for RVGE were reported, with a mean hospital stay of
3.5 days. The population-based hospitalisation RVGE incidence rate was 195.8 per 100,000 children aged ≤5 years
(lower than other European countries).
Conclusions: RVGE is an important cause of paediatric hospitalisation in the Veneto Region. The data reaffirm the
substantial burden of rotavirus hospitalisations in children and the potential health benefits of the vaccination as
well as the possibility of adding rotavirus vaccination to the current schedule.
Background
Rotavirus is the main cause of severe acute gastroenteri-
tis (AGE) among children ≤5 years [1,2]. Improvements
in sanitation and hygiene have not changed the global
incidence of this disease, pointing to vaccination as the
most effective way to achieve disease control [3,4].
Worldwide, the incidence of rotavirus gastroenteritis
(RVGE) is similar both in developed and developing
countries [2,5].
In industrialised countries, where access to health care
is generally good, mortality due to RVGE is very low
[6,7]. Nevertheless, the burden of disease remains con-
siderable, being a major cause of hospitalization among
children. In these countries, a model developed by the
European Centre for Disease Prevention and Control
estimates an overall rotavirus hospitalisation rate of 445
per 100,000 children younger than 5 years of age [3].
Globally, rotavirus is more common in the cooler
months, but seasonal peaks can vary broadly and may
occur from autumn to spring [8,9]. Rotavirus is primar-
ily transmitted by fecal-oral route and is highly conta-
gious. Almost all children are infected at least once
before the age of 5 [3]. Its typical symptoms vary from a
mild illness with self-limiting watery diarrhoea to severe
diarrhoea accompanied by vomiting and fever, with risks
of dehydration [2].
Gastrointestinal infections in children have a signifi-
cant impact on the families and on society. They result
in increased medical expenditures, lost productivity and
childcare [10].
Vaccination is considered the most effective public
health strategy to prevent rotavirus infection and reduce
disease burden, so that the World Health Organisation
strongly recommends inclusion of rotavirus vaccines
into national immunisation programs in the regions
where vaccine efficacy data suggest a significant public
health impact and where appropriate infrastructure and
finance mechanisms are available [11].
This study evaluates the epidemiological impact of
RVGE hospitalisation in the Veneto Region during the
period spanning from 2000-2007 along with the asso-
ciated cost. The analysis was conducted in an area
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nization programmes and is an attempt to assess the
potential benefits of such introduction.
Methods
To estimate the annual rates of RVGE associated hospi-
talization a retrospective population-based study was
conducted analysing data collected from the hospital
discharge database (HDD) of the Veneto Region (North
East Italy), covering the 100% of discharges from all hos-
pitals. The data were acquired in electronic form and
were anonymous. The population used as denominator
comes from the 2001 census data (National Institute of
Statistics) and for the remaining years from the Office
for Regional Statistics.
Cases of RVGE were identified using the International
Classification of Diseases, nine revision, Clinical Modifi-
cation (ICD-9-CM). Acute gastroenteritis discharges
were identified by the codes ICD-9-CM 001 to 009,
whereas RVGE discharges were identified by the code
008.61, eliminating secondary diagnosis so as to exclude
nosocomial cases [12]. AGE cases of unspecified etiology
were identified by code 009.1. The hospitalisation inci-
dence due to rotavirus gastroenteritis and the mean hos-
pital stay were calculated per 100,000 population.
Mortality refers to inpatient mortality and does not con-
sider the specific death cause.
In order to correlate the rate of hospitalization with
the seasonal pattern the mean temperature by month is
reported. Temperature data were supplied by the Regio-
nal Agency for environmental prevention and protection
and derived from 14 monitoring stations located in dif-
ferent areas of the Veneto Region: 12 on plain (<300 m)
and 2 on hill (300-600 m).
The direct costs associated to RVGE hospitalisations
were estimated through DRG (Diagnosis Related Group)
reimbursement rates. Rotavirus gastroenteritis has been
referred to the DRG code 184 (esophagitis, gastroenteri-
tis, and miscellaneous digestive disorders, age < 18) by
considering only the first diagnosis. According to the
Veneto regional DRG reimbursement system (HCFA-
DRG, 24
th edition) the estimated cost of each RVGE
hospital admission is 1,262 €.
The quantitative variables are expressed as the mean
and the standard deviation (SD). The Odds Ratio (OR)
was used to analyse variables such as age, sex and hospi-
tal stay, and the Chi square test for trend to analyse the
seasonal pattern. A P value <0.05 was considered statis-
tically significant.
The Hospital Services of the Veneto Region collect
HDD. The data contained is recorded with the patient’s
consent and can be used as aggregated data for scientific
studies without further authorizations. Furthermore the
study complies with the Declaration of Helsinki and
with the Italian Law Decree n. 196/2003 to protect per-
sonal data.
Results
Over the 8-year study period, a total of 26,202 hospital
discharges due to infectious gastroenteritis were regis-
tered (67.1 cases per 100,000 population). The mean
hospital stay was 4.7 ± 5.7 days.
Of these hospitalisations, 14,201 (54.2%) occurred
among children aged ≤5 years. Hospital rate among chil-
dren was significantly higher than that in other age
groups (OR = 20.8; [95% confidence interval: 20.30,
21.33]; p < 0.05) and the mean hospital stay halved (3.3
± 2.4 days vs. 6.5 ± 5.7 days; p < 0.05).
Excluding AGE cases of unspecified etiology (37.8%), a
total of 28.6% of all discharges due to AGE of specified
etiology in children aged ≤5 years were attributable to
RVGE.
The proportion of hospital discharges due to rotavirus
gastroenteritis in different age groups was examined in
order to assess age-specific rotavirus disease burden
(Table 1). The majority of cases were reported among
children ≤5 years, in particular infants ≤1 year which
registered a significantly higher hospital rate and mean
hospital stay than the other age groups (p < 0.05).
During the study period 1 death occurred in a 2-year-
old male.
Table 2 shows the number of RVGE discharges, the
mean hospital stay and hospital rate per 100,000 among
children aged ≤5 years: minimal variations of the mean
hospital stay were accounted against a significant hospi-
tal rate reduction (Chi-square for trend = 116.1; p < 0.05).
Most RVGE cases occurred during the rotavirus sea-
son; infections peaked in winter and spring and were
l o w e ri ns u m m e r( F i g u r e1 ) ,w i t h5 3 . 9 %o fd i s c h a r g e s
occurring in February-April and 21.4% in March.
The incidence of RVGE admissions in the Veneto
Region among children aged ≤5 years was 195.8 per
100,000, ranking as the first cause of acute
Table 1 Hospital discharges attributable to rotavirus
gastroenteritis (RVGE) by age groups
Age
group
Number of
hospitalisations
due to RVGE (%)
Mean stay
(SD)
RVGE hospital rate
per 100,000
0-5 years 4,119 (91%) 3.5 (3.5) 195.8
<1
year
969 (21%) 3.9 (3.3) 271.1
1-5
years
3,150 (70%) 3.4 (3.2) 180.4
Other
ages
422 (9%) 3.3 (3.1) 1.1
Total 4,541 (100%) 3.5 (3.7) 11.6
SD: Standard deviation.
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mean hospital stay is equal to 3.5 days.
Over the 8-year study period, the economic impact of
RVGE varied between 460,630 € and 1,009,600 €.
Overall the cost of hospital admission was 5,730,742 €
and the 91% of these were used for children ≤5 years.
Discussion
The incidence of rotavirus infection in Italy seems sub-
stantially underestimated. As in most European coun-
tries detection of rotavirus is not notifiable so disease
estimates are based on hospital discharge data [13]. A
recent European model estimated about 10,000 hospita-
lisations, 80,000 physician visits, 320,000 episodes and
11 deaths occurring each year in Italy [5].
Our RVGE hospitalisation updated assessment con-
firms that rotavirus is a major cause of AGE among
children aged ≤5 years, accounting 91% of RVGE cases.
The overall rate of hospitalisation for RVGE in our
region among children aged ≤5 years is lower than the
European mean (198 per 100,000 versus 300 per
100,000) and comparable with analogous studies con-
ducted in other Italian regions [13-15]. However, the
comparison with studies using national HDD should be
made with caution because the timeframe, the at-risk
population and the geographical districts do not overlap.
The mean hospital stay, equal to 3.5 days, is shorter than
the European mean (4.8 days) but lies within the European
range (2-9.5 days) [16]. Rotavirus gastroenteritis showed a
considerable burden of hospital admissions and a clear
seasonal distribution, with peak incidence from winter to
spring as highlighted in other European countries [17,18].
Table 2 Hospital discharges by rotavirus gastroenteritis
(RVGE) among children ≤5 years from year 2000 to 2007
Year Number of
hospitalisations
due to RVGE
Mean
stay
(SD)
RVGE
hospital rate
per 100,000
Proportion of
hospitalisations
due to RVGE in
0-5 years
2000 455 3.6
(2.9)
182.4 89%
2001 731 3.7
(3.1)
291.3 91%
2002 623 3.6
(3.2)
243.8 90%
2003 519 3.5
(3.1)
199.4 92%
2004 399 3.4
(3.4)
149.7 90%
2005 633 3.4
(3.3)
234 93%
2006 430 3.4
(2.7)
156.2 90%
2007 329 3.6
(3.4)
119.5 90%
Total 4,119 3.5
(3.5)
195.8 91%
SD: Standard deviation.
Figure 1 Rotavirus hospitalisation rates of children ≤5 years and The mean monthly temperatures in the Veneto Region.
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Page 3 of 5Although most of rotavirus infections are successfully
treated in a primary care setting, hospitalisation-related
costs account for 80% of the budget destined to rota-
virus therapy. A recent study assessed direct medical
costs for the Italian Health System being around 30 mil-
l i o ne u r op e ry e a r[ 1 9 ] .O u rs t u d yr e p o r t st h a tD R G
costs associated to hospital admissions due to RVGE are
lower than the European mean. European data on the
expenditure of rotavirus disease showed that hospital
admission is a main cost driver, but non-medical costs
are not negligible [16]. However, our study does not
estimate social costs, indirect costs and family expendi-
ture costs.
In Italy the national vaccination programme does not
include rotavirus universal vaccination for newborns
despite safe and effective attenuated rotavirus vaccines
[Rotarix (GlaxoSmithKline Biologicals s.a.) and Rota-
Teq (Sanofi Pasteur MSD, SNC)] have been available in
Europe since 2006 [20-22]. In view of the lack of inter-
ference with co-administered childhood vaccines both
could be included within the existing regional and
national immunization programmes. Hence Italian
public health authorities should consider the opportu-
nity of offering these vaccines to all newborns within 6
months of age [23,24]. Several potential strategies to
provide rotavirus vaccination are possible. Firstly, an
offer concerning children at greater risk of severe ill-
ness (i.e.: low birth weight and preterm infants) can be
considered for budgetary reasons. However according
to a study conducted in the United States even if those
risk factors significantly predicted infants at high risk
for hospitalization with viral AGE in the first year of
life were neither sufficiently sensitive nor specific to be
used to create a focused rotavirus immunization policy
[25]. Secondly vaccination could be offered free of
charge or in co-payment. As other vaccines routinely
offered in Italy Rotavirus vaccine can be administered
in primary care settings throughout Departments of
prevention and/or paediatricians ambulatories. This
choice requires a careful evaluation of local health sys-
tems organisation, expenditures and expected coverage
have to be considered. The decision on which strategy
put into practice should be taken by national and
regional authorities according to scientific evidence,
international recommendations, local epidemiology and
primary care organisations. In addition it needs to be
preceded by a cost-effectiveness analysis assessing
sustainability.
The strengths of the study include a large study popu-
lation and the provision of epidemiological information
on severe RVGE disease in the area which constitutes a
valuable baseline for the future assessment of rotavirus
vaccine impact.
There are several limitations of our study. Firstly using
administrative data could lead to an underestimation of
the RVGE incidence because while HDD are character-
ized by a high specificity, sensitivity could be lower.
However in Italy, as in many European countries, rota-
virus is not a notifiable disease and estimates are based
mainly on hospital discharge data. The HDD is charac-
terized by high specificity and low sensitivity [14]
because of a large number of discharges codified by
non-specific codes. The absence of an etiologic diagnosis
could be related to budgetary reasons, to not enough
sensitive laboratory tests as well as to empirical treat-
ment [2,17]. Furthermore, the hospitalisation rate could
be underestimated because secondary diagnosis of rota-
virus gastroenteritis were not taken into account. Some
authors demonstrated that the incidence of RVGE
admissions grows consistently considering both diagno-
sis but it is feasible that the second diagnosis have a
nosocomial origin [12,13].
Conclusions
RVGE represents an important cause of paediatric hos-
pitalisation in the Veneto Region, though the impact of
RVGE admissions is underestimated, primarily due to a
low sensitivity of hospital discharges and an active sur-
veillance system should be implemented. Our data reaf-
firm the burden of rotavirus hospitalisations in children
aged ≤5 years and the potential health benefits of the
vaccination introduction that should be offered to all
newborns within 6 months of age.
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